Clinical Trial Update: Oral GW766944 (Oral CCR3 Antagonist) [Phase 2]

View source ↗

Summary

The Phase 2 trial of GW766944, an oral CCR3 antagonist, for asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• GW766944

Snippet

Sponsor: GlaxoSmithKline | Conditions: Asthma | Phase 2 | Status: COMPLETED